淀粉样蛋白PET临床效用结局的现状与未来展望
该系统综述纳入截至2020年4月的32项淀粉样蛋白PET研究,分析临床效用结局的分类、定义与评估方法。结果显示以临床医生为中心的结局最常见(78%),患者/照护者中心和健康经济学结局较少且定义与评估不一致。作者建议更广泛地纳入利益相关者以系统定义和评估临床效用结局。
要点
- 淀粉样蛋白PET临床效用结局以临床医生为中心者占78%,患者/照护者中心占28%,健康经济学占16%。
- 仅ABIDE研究明确在小组讨论中纳入利益相关者参与结局定义。
- 各研究结局评估工具不一致,共使用26种不同工具且无正式选择依据。
核心结论
- 当前验证淀粉样蛋白PET的研究已评估临床效用结局,但非临床医生为中心的结局不一致。
- 更广泛的利益相关者参与可能有助于更全面系统地定义和评估临床效用结局,并为淀粉样蛋白PET的报销决策收集证据。
研究设计与样本
- 系统综述纳入截至2020年4月发表的、包含临床效用结局的淀粉样蛋白PET研究,共32项符合条件。
- 提取并分析结局类别、定义及评估方法。
主要发现
- 结局类别:临床医生为中心25/32项(78%),患者/照护者为中心9/32项(28%),健康经济学为中心5/32项(16%)。
- 临床医生为中心结局主要为增量诊断价值(25/32,78%)和患者管理改变(17/32,53%)。
- 患者/照护者为中心结局考虑淀粉样蛋白PET诊断披露后的痛苦(8/32,25%),包括量化操作负担对患者结局的影响(1/8,12.5%)、结果披露的影响(6/8,75%)及基于生物标志物诊断的心理影响(75%)。
- 健康经济学结局聚焦于实现高置信度病因诊断的成本(5/32,16%)和对生活质量的影响(1/32,3%)。
关键数值与推荐
- 结局定义主要由临床研究者完成,仅ABIDE研究明确在小组讨论中纳入利益相关者。
- 所有结局类别在各研究间操作化不一致,共使用26种不同工具且无正式选择依据。
临床怎么用
- 临床医生在解读淀粉样蛋白PET研究时需注意临床效用结局定义和评估工具的高度异质性。
- 未来研究和临床实践应推动利益相关者参与结局定义,以支持淀粉样蛋白PET的报销决策。
局限性
- 仅纳入截至2020年4月发表的文献,可能未覆盖后续研究。
- 非临床医生为中心的结局定义和评估不一致,限制了跨研究比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included outcomes of clinical utility. We extracted and analyzed (a) outcome categories, (b) their definition, and (c) their methods of assessment. RESULTS: Thirty-two studies were eligible. (a) Outcome categories were clinician-centered (found in 25/32 studies, 78%), patient-/caregiver-centered (in 9/32 studies, 28%), and health economics-centered (5/32, 16%). (b) Definition: Outcomes were mainly defined by clinical researchers; only the ABIDE study expressly included stakeholders in group discussions. Clinician-centered outcomes mainly consisted of incremental diagnostic value (25/32, 78%) and change in patient management (17/32, 53%); patient-/caregiver-centered outcomes considered distress after amyloid-pet-based diagnosis disclosure (8/32, 25%), including quantified burden of procedure for patients' outcomes (n = 8) (1/8, 12.5%), impact of disclosure of results (6/8, 75%), and psychological implications of biomarker-based diagnosis (75%); and health economics outcomes focused on costs to achieve a high-confidence etiological diagnosis (5/32, 16%) and impact on quality of life (1/32, 3%). (c) Assessment: all outcome categories were operationalized inconsistently across studies, employing 26 different tools without formal rationale for selection. CONCLUSION: Current studies validating amyloid-PET already assessed outcomes for clinical utility, although non-clinician-based outcomes were inconsistent. A wider participation of stakeholders may help produce a more thorough and systematic definition and assessment of outcomes of clinical utility and help collect evidence informing decisions on reimbursement of amyloid-PET.
引用
- Cotta Ramusino M, Perini G, Altomare D, et al. Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. Eur J Nucl Med Mol Imaging. 2021. PMID: 33594474. doi:10.1007/s00259-020-05187-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。